UTHR
United Therapeutics CorporationNASDAQHealthcare$564.81-0.96%ClosedMarket Cap: $24.75B
As of 2026-04-06
Valuation
P/E (TTM)
18.55
PEG
1.59
P/B
3.49
P/S
7.71
EV/EBITDA
12.71
DCF Value
$718.61
FCF Yield
4.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.9%
Operating Margin
46.9%
Net Margin
41.9%
ROE
19.3%
ROA
16.9%
ROIC
15.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $790.2M | 86.9% | $356.7M | $364.3M | $7.66 | — |
| FY 2025 | $3.18B | 87.9% | $1.49B | $1.33B | $27.86 | — |
| Q3 2025 | $799.5M | 87.4% | $388.5M | $338.7M | $7.16 | — |
| Q2 2025 | $798.6M | 89.0% | $364.5M | $309.5M | $6.41 | — |
| Q1 2025 | $794.4M | 88.4% | $382.8M | $322.2M | $6.63 | — |
| Q4 2024 | $735.9M | 89.7% | $357.7M | $301.3M | $6.19 | — |
| FY 2024 | $2.88B | 89.2% | $1.38B | $1.20B | $24.64 | — |
| Q3 2024 | $748.9M | 88.9% | $343.1M | $309.1M | $6.39 | — |
| Q2 2024 | $714.9M | 89.1% | $319.9M | $278.1M | $5.85 | — |
| Q1 2024 | $677.7M | 89.2% | $356.3M | $306.6M | $6.17 | — |
| Q4 2023 | $614.7M | 88.4% | $260.1M | $217.1M | $4.36 | — |
| FY 2023 | $2.33B | 88.9% | $1.18B | $984.8M | $19.81 | — |